RU2006133320A - Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов - Google Patents
Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов Download PDFInfo
- Publication number
- RU2006133320A RU2006133320A RU2006133320/04A RU2006133320A RU2006133320A RU 2006133320 A RU2006133320 A RU 2006133320A RU 2006133320/04 A RU2006133320/04 A RU 2006133320/04A RU 2006133320 A RU2006133320 A RU 2006133320A RU 2006133320 A RU2006133320 A RU 2006133320A
- Authority
- RU
- Russia
- Prior art keywords
- azabicyclo
- amide
- carboxylic acid
- oct
- ethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 43
- DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 title 1
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 25
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 7
- 239000012453 solvate Substances 0.000 claims abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical group 0.000 claims abstract 6
- 150000002431 hydrogen Chemical group 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims abstract 2
- -1 4-acetylpiperazin-1-yl Chemical group 0.000 claims 47
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 39
- FHUPHXAYPNYFIU-UHFFFAOYSA-N 1-propan-2-ylindazole-3-carboxylic acid Chemical compound C1=CC=C2N(C(C)C)N=C(C(O)=O)C2=C1 FHUPHXAYPNYFIU-UHFFFAOYSA-N 0.000 claims 36
- 150000001408 amides Chemical class 0.000 claims 13
- 238000000034 method Methods 0.000 claims 7
- IHZRQQYHYALFRG-UHFFFAOYSA-N 1-propan-2-ylindazole-3-carboxamide Chemical compound C1=CC=C2N(C(C)C)N=C(C(N)=O)C2=C1 IHZRQQYHYALFRG-UHFFFAOYSA-N 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 4
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 230000004899 motility Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 claims 1
- IEIAQSWMJMZELU-UHFFFAOYSA-N 5-fluoro-1-propan-2-ylindazole-3-carboxylic acid Chemical compound FC1=CC=C2N(C(C)C)N=C(C(O)=O)C2=C1 IEIAQSWMJMZELU-UHFFFAOYSA-N 0.000 claims 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000013617 idiopathic gastroparesis Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- OEQJOYQHIGIVTN-UHFFFAOYSA-N tert-butyl nonanoate Chemical class CCCCCCCCC(=O)OC(C)(C)C OEQJOYQHIGIVTN-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54570204P | 2004-02-18 | 2004-02-18 | |
| US60/545,702 | 2004-02-18 | ||
| PCT/US2005/005070 WO2005080389A1 (en) | 2004-02-18 | 2005-02-17 | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006133320A true RU2006133320A (ru) | 2008-03-27 |
Family
ID=34886184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133320/04A RU2006133320A (ru) | 2004-02-18 | 2005-02-17 | Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7351704B2 (https=) |
| EP (1) | EP1718643A1 (https=) |
| JP (1) | JP2007523175A (https=) |
| KR (1) | KR20060132727A (https=) |
| CN (1) | CN1922175A (https=) |
| AR (1) | AR047681A1 (https=) |
| AU (1) | AU2005214368A1 (https=) |
| BR (1) | BRPI0507791A (https=) |
| CA (1) | CA2553696A1 (https=) |
| IL (1) | IL177059A0 (https=) |
| MA (1) | MA28435B1 (https=) |
| NO (1) | NO20064156L (https=) |
| RU (1) | RU2006133320A (https=) |
| TW (1) | TW200533348A (https=) |
| WO (1) | WO2005080389A1 (https=) |
| ZA (1) | ZA200606479B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| ATE441646T1 (de) * | 2004-11-05 | 2009-09-15 | Theravance Inc | 5-ht4-rezeptoragonistenverbindungen |
| EP1807423B1 (en) * | 2004-11-05 | 2009-05-20 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| ATE469897T1 (de) * | 2004-12-22 | 2010-06-15 | Theravance Inc | Indazolcarbonsäureamidverbindungen |
| WO2006088988A1 (en) * | 2005-02-17 | 2006-08-24 | Theravance, Inc. | Crystalline form of an indazole-carboxamide compound |
| NZ560828A (en) * | 2005-03-02 | 2011-01-28 | Theravance Inc | Quinolinone compounds as 5-HT4 receptor agonists |
| US7317022B2 (en) * | 2005-06-07 | 2008-01-08 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists |
| WO2007102883A2 (en) * | 2005-10-25 | 2007-09-13 | Smithkline Beecham Corporation | Chemical compounds |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| CA2637214C (en) * | 2006-02-16 | 2014-04-22 | Theravance, Inc. | Process for preparing 8-azabicylo[3.2.1]octan-3-one intermediates to 5-ht4 receptor agonist compounds |
| KR100812499B1 (ko) * | 2006-10-16 | 2008-03-11 | 이도훈 | 항경련제 |
| EP2121679B1 (de) * | 2007-02-23 | 2015-04-15 | K.H.S. Pharma Holding Gmbh | Verfahren zur herstellung von azoniaspironortropinestern |
| KR20100124262A (ko) * | 2008-02-13 | 2010-11-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 비시클로아민 유도체 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| CN103748087A (zh) * | 2011-06-07 | 2014-04-23 | 大日本住友制药株式会社 | 吲唑和吡咯并吡啶衍生物和其药学用途 |
| CA2867043A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| JP2014133739A (ja) * | 2012-12-12 | 2014-07-24 | Dainippon Sumitomo Pharma Co Ltd | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 |
| CA2957498C (en) * | 2014-08-16 | 2019-02-12 | Suven Life Sciences Limited | Process for large scale production of 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1h-indazole oxalate |
| WO2021046789A1 (zh) * | 2019-09-12 | 2021-03-18 | 广东东阳光药业有限公司 | 吲唑-甲酰胺衍生物及其用途 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321378A (en) * | 1979-01-16 | 1982-03-23 | Delalande S.A. | 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives |
| US4937247A (en) * | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
| HU895334D0 (en) * | 1986-07-30 | 1990-01-28 | Sandoz Ag | Process for the preparation of nasal pharmaceutical compositions |
| US4948803A (en) * | 1986-11-21 | 1990-08-14 | Glaxo Group Limited | Medicaments for treatment on prevention of withdrawal syndrome |
| GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| IT1231413B (it) | 1987-09-23 | 1991-12-04 | Angeli Inst Spa | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht |
| US5223511A (en) * | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| IT1226389B (it) * | 1988-07-12 | 1991-01-15 | Angeli Inst Spa | Nuovi derivati ammidinici e guanidinici |
| US5017573A (en) * | 1988-07-29 | 1991-05-21 | Dainippon Pharmaceutical Co., Ltd. | Indazole-3-carboxylic acid derivatives |
| EP0410509A1 (en) * | 1989-07-25 | 1991-01-30 | Duphar International Research B.V | New substituted 1H-indazole-3-carboxamides |
| JPH045289A (ja) | 1990-04-24 | 1992-01-09 | Hokuriku Seiyaku Co Ltd | アミド化合物 |
| JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
| HU211081B (en) * | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| DE69113284T2 (de) * | 1990-12-28 | 1996-02-22 | Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo | Chinolinderivat. |
| WO1993003725A1 (en) | 1991-08-20 | 1993-03-04 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
| EP0603220A1 (en) * | 1991-09-12 | 1994-06-29 | Smithkline Beecham Plc | Azabicyclic compounds as 5-ht 4? receptor antagonists |
| MX9305947A (es) * | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
| EP0670319A4 (en) * | 1992-11-20 | 1996-01-17 | Thaisho Pharmaceutical Co Ltd | HETEROCYCLIC COMPOUNDS. |
| TW251287B (https=) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9310582D0 (en) * | 1993-05-22 | 1993-07-07 | Smithkline Beecham Plc | Pharmaceuticals |
| AU679336B2 (en) * | 1994-02-28 | 1997-06-26 | Taisho Pharmaceutical Co., Ltd. | Heterocyclic compound |
| US5864039A (en) * | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JP3829879B2 (ja) * | 1994-05-18 | 2006-10-04 | 大正製薬株式会社 | キノリンカルボン酸誘導体 |
| US5684003A (en) * | 1994-10-20 | 1997-11-04 | Nisshin Flour Milling Co., Ltd. | 5-HT4 receptor agonists |
| JP3829880B2 (ja) | 1994-12-27 | 2006-10-04 | 大正製薬株式会社 | 化学中間体 |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| US5654320A (en) * | 1995-03-16 | 1997-08-05 | Eli Lilly And Company | Indazolecarboxamides |
| DE69627323T2 (de) * | 1995-05-31 | 2004-01-15 | Nisshin Seifun Group Inc | Indazolderivate mit einer cyclischen aminogruppe |
| ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| TW402591B (en) * | 1997-07-11 | 2000-08-21 | Janssen Pharmaceutica Nv | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| US5914405A (en) * | 1997-10-07 | 1999-06-22 | Eli Lilly And Company | Process for preparing 3-substituted indazoles |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| FR2769915B1 (fr) | 1997-10-21 | 2000-10-13 | Synthelabo | Derives d'indazole tricycliques, leur preparation et leur application en therapeutique |
| IT1298271B1 (it) | 1998-02-18 | 1999-12-20 | Boehringer Ingelheim Italia | Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico |
| WO1999055674A1 (en) * | 1998-04-28 | 1999-11-04 | Dainippon Pharmaceutical Co., Ltd. | 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds |
| KR100413150B1 (ko) * | 1998-09-10 | 2003-12-31 | 에프. 호프만-라 로슈 아게 | 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체 |
| TW570920B (en) * | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| FR2792318B1 (fr) | 1999-04-16 | 2001-06-15 | Synthelabo | Derives d'indazole, leur preparation et leur application en therapeutique |
| WO2000064441A2 (en) * | 1999-04-28 | 2000-11-02 | Respiratorius Ab | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
| IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
| IT1313660B1 (it) | 1999-10-01 | 2002-09-09 | Dompe Spa | Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani. |
| AU2002212888A1 (en) | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
| US6624162B2 (en) * | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| PL372968A1 (en) | 2002-04-08 | 2005-08-08 | Pfizer Inc. | Tropane derivatives as ccr5 modulators |
| US6696468B2 (en) * | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| DOP2003000703A (es) * | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| JP2006502180A (ja) | 2002-09-20 | 2006-01-19 | ファイザー株式会社 | ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物 |
| BRPI0409592A (pt) * | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| WO2005000837A1 (en) | 2003-06-19 | 2005-01-06 | Janssen Pharmaceutica N.V. | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists |
| JO2478B1 (en) | 2003-06-19 | 2009-01-20 | جانسين فارماسوتيكا ان. في. | (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists |
| UA86204C2 (uk) | 2003-09-03 | 2009-04-10 | Пфайзер Инк. | Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність |
| DE602004026095D1 (de) | 2003-11-24 | 2010-04-29 | Pfizer | Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung |
| DE602005005167T2 (de) | 2004-01-29 | 2009-04-30 | Pfizer Inc. | 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| ATE441646T1 (de) * | 2004-11-05 | 2009-09-15 | Theravance Inc | 5-ht4-rezeptoragonistenverbindungen |
-
2005
- 2005-02-15 TW TW094104343A patent/TW200533348A/zh unknown
- 2005-02-17 EP EP05723216A patent/EP1718643A1/en not_active Withdrawn
- 2005-02-17 WO PCT/US2005/005070 patent/WO2005080389A1/en not_active Ceased
- 2005-02-17 BR BRPI0507791-5A patent/BRPI0507791A/pt not_active IP Right Cessation
- 2005-02-17 AU AU2005214368A patent/AU2005214368A1/en not_active Abandoned
- 2005-02-17 CA CA002553696A patent/CA2553696A1/en not_active Abandoned
- 2005-02-17 AR ARP050100560A patent/AR047681A1/es unknown
- 2005-02-17 CN CNA200580005307XA patent/CN1922175A/zh active Pending
- 2005-02-17 KR KR1020067019088A patent/KR20060132727A/ko not_active Withdrawn
- 2005-02-17 RU RU2006133320/04A patent/RU2006133320A/ru not_active Application Discontinuation
- 2005-02-17 JP JP2006554207A patent/JP2007523175A/ja active Pending
- 2005-02-17 US US11/060,195 patent/US7351704B2/en active Active
-
2006
- 2006-07-25 IL IL177059A patent/IL177059A0/en unknown
- 2006-08-03 ZA ZA200606479A patent/ZA200606479B/en unknown
- 2006-08-18 MA MA29276A patent/MA28435B1/fr unknown
- 2006-09-14 NO NO20064156A patent/NO20064156L/no not_active Application Discontinuation
-
2008
- 2008-02-04 US US12/012,579 patent/US7674908B2/en not_active Expired - Lifetime
-
2010
- 2010-01-19 US US12/689,763 patent/US8044045B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
Also Published As
| Publication number | Publication date |
|---|---|
| IL177059A0 (en) | 2006-12-10 |
| MA28435B1 (fr) | 2007-02-01 |
| NO20064156L (no) | 2006-11-10 |
| US7351704B2 (en) | 2008-04-01 |
| EP1718643A1 (en) | 2006-11-08 |
| KR20060132727A (ko) | 2006-12-21 |
| US20100261716A1 (en) | 2010-10-14 |
| WO2005080389A1 (en) | 2005-09-01 |
| AU2005214368A1 (en) | 2005-09-01 |
| CN1922175A (zh) | 2007-02-28 |
| US20080146807A1 (en) | 2008-06-19 |
| US20050197335A1 (en) | 2005-09-08 |
| BRPI0507791A (pt) | 2007-07-17 |
| JP2007523175A (ja) | 2007-08-16 |
| US7674908B2 (en) | 2010-03-09 |
| CA2553696A1 (en) | 2005-09-01 |
| TW200533348A (en) | 2005-10-16 |
| US8044045B2 (en) | 2011-10-25 |
| AR047681A1 (es) | 2006-02-01 |
| ZA200606479B (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006133320A (ru) | Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов | |
| JP2007523175A5 (https=) | ||
| JP4796552B2 (ja) | ムスカリン性アセチルコリン受容体アンタゴニスト | |
| US10377751B2 (en) | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | |
| RU2006139053A (ru) | Хинолинонкарбоксамидные соединения в качестве агонистов 5-ht4 рецепторов | |
| US7902220B2 (en) | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | |
| RU2007128061A (ru) | Индазол-карбоксамидные соединения | |
| AR019478A1 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos. | |
| JP2007532546A5 (https=) | ||
| SK16698A3 (en) | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)- -1-propanolmethanesulfonate trihydrate | |
| JP5042028B2 (ja) | キノリノン−カルボキサミド化合物 | |
| JP2008518965A5 (https=) | ||
| JPH10316567A (ja) | 過敏性腸症候群の症状の治療用のｎｋ−１受容体アンタゴニスト | |
| JP2009512624A5 (https=) | ||
| JP2005505625A (ja) | 新規な置換された４−フェニル−４−［１ｈ−イミダゾール−２−イル］−ピペリジン誘導体および選択的非ペプチドデルタオピオイドアゴニストとしてのそれらの使用 | |
| RU2007116950A (ru) | Производные тиенопиридинона и способы лечения | |
| Mustazza et al. | Nociceptin/orphanin FQ peptide (NOP) receptor modulators: an update in structure-activity relationships | |
| EP1478356A2 (en) | Therapeutic compounds | |
| AU2007203078B2 (en) | Muscarinic acetylcholine receptor antagonists | |
| WO1997025043A1 (en) | A method of treating hypercholesterolemia and related disorders | |
| HRP950549A2 (en) | A method of treating urinary bladder disfunctions | |
| JP2009516745A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101013 |